Please assess the completion status of the following clinical trial:

Trial Title: A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Willingness to sign a written informed consent~* Chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2009~* Chinese or Malay or Indian ethnicity~* History of chronic obstructive pulmonary disease symptoms for at least 12 months prior to baseline visit V0~* Forced expiratory volume in the first second/ Forced vital capacity (FEV1/FVC) ratio (post-bronchodilator) \< 70%~* Forced expiratory volume in the first second (FEV1) (post-bronchodilator) \< 50 % of predicted~* Former smoker (defined as: smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years~Main Exclusion Criteria:~* Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics not stopped at V0~* Lower respiratory tract infection not resolved 4 weeks prior to the baseline visit V0~* History of asthma diagnosis in patients \< 40 years of age or relevant lung disease other than COPD~* Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline visit V0~* Known alpha-1-antitrypsin deficiency

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: EXPERIMENTAL): Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).